# IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites

> **NCT05268172** · PHASE1 · RECRUITING · sponsor: **Affiliated Hospital of Jiangnan University** · enrollment: 40 (estimated)

## Conditions studied

- Pleural Effusion, Malignant

## Interventions

- **DRUG:** IFN-γ and CIK cells, Tcm cells or CAR T cells

## Key facts

- **NCT ID:** NCT05268172
- **Lead sponsor:** Affiliated Hospital of Jiangnan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-20
- **Primary completion:** 2024-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-05-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05268172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05268172, "IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05268172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*